US 11896654
DNA monoclonal antibodies targeting checkpoint molecules
granted A61KA61K2039/505A61K2039/53
Quick answer
US patent 11896654 (DNA monoclonal antibodies targeting checkpoint molecules) held by Inovio Pharmaceuticals, Inc. expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Inovio Pharmaceuticals, Inc.
- Grant date
- Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K2039/505, A61K2039/53, A61K31/7088, A61K39/0011